RTW’s Rod Wong on how China has (and hasn’t) changed his firm’s investment strategy

RTW's Rod Wong defends China in-licensing, argues it grows the US biotech pie, and responds to critics of the Serapha Bio launch.

Raccontata daendpoints.news